
Indoco enters new drug research field
Indoco Remedies, the Rs 400 crore makers of anti-infectives and pain management medicines is exploring options in new drugs through chemistry and biotechnology. The company, which set up its research and development (R&D) facility in Rabale, Navi Mumbai, in 2006, is planning to leverage its experience as a contract research organisation (CRO) to set up expertise in researching new medicines.
The company is planning to ramp up its staff strength at its R&D centre to about 200 by next year, and would hire staff to set up a 'lead library', a first step towards starting off on new drug research. It is currently working with Japanese manufacturers on various contract research projects.
“Our chairman (Suresh G Kare) says we might be late, but by just a couple of years,” said Dr Ketan Vyas, vice president, R&D. Vyas has been entrusted the task to turn Indoco from a predominantly API and cheap drug-making and marketing company to a highly focussed, research driven organisation.
The Indoco scrip closed at Rs 286.75, up 2.78 per cent or Rs 7.75 at end of trade Tuesday. The company is exploring these options to increase revenues in a market where API margins are becoming difficult to maintain. API, or Active Pharmaceutical Ingredients, are the basic chemicals for drugs.
Global oil prices have spiked to almost four times what it was last year, and is putting severe pressure on the price of solvents used to make solutions for API. “Solvents are petro-chemical by products, and there is no other way of preparing solvents,” Vyas said.

DHFL resolution: Lenders approve Piramal's bid

Indigo Paints to come up with its IPO on January 20. All you need to know

Indian Railway Finance Corporation IPO opens tomorrow

Amazon Prime Video to continue investing in local content, expanding reach

Plea in HC against Lakshmi Vilas Bank-DBS merger

'Can't read your personal conversation: WhatsApp shares status amid backlash

Demand to rationalise GST on food delivery business to 5%

Indian economy may contract by 25 per cent in current fiscal: Expert

Bank credit grows 3.2 pc in first nine months of FY21

Six of top-10 most valued firms add over ₹1.13 lakh crore

UK's Deliveroo raises $180 million from investors, valued at $7 billion

WhatsApp defers new policy on info sharing

Bitcoin swings undermine CFO case for converting cash to cryptocurrency

HDFC Bank penalises its executive for inadvertently selling shares
